The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 7,288,824 |
| Interest earned on cash held in trust account | 8,484,511 |
| Change in fair value of over-allotment liability | 0 |
| Payment of operating costs through promissory note | 0 |
| Prepaid expenses | -88,005 |
| Long term prepaid insurance | -113,275 |
| Accounts payable and accrued expenses | -33,545 |
| Accrued offering costs | -179,984 |
| Due to related party | 785,857 |
| Net cash used in operating activities | -422,079 |
| Investment of cash in trust account | 0 |
| Cash withdrawn from trust account for allowable working capital purposes | 500,000 |
| Net cash provided by investing activities | 500,000 |
| Proceeds from sale of units, net of underwriting discounts paid | 0 |
| Proceeds from sale of private placement units | 0 |
| Repayment of promissory noterelated party | 0 |
| Net cash provided by financing activities | 0 |
| Net change in cash | 77,921 |
| Cash beginning of period | 1,357,044 |
| Cash end of period | 1,434,965 |
Oaktree Acquisition Corp. III Life Sciences (OACCW)
Oaktree Acquisition Corp. III Life Sciences (OACCW)